01928nas a2200457   4500000000100000008004100001260001300042653001500055653001000070653000900080653002600089653001000115653003000125653001100155653002200166653001100188653002300199653001200222653000900234653001600243653001400259653001400273653001300287100001900300700001300319700001800332700001800350700001700368700001400385700001500399700001400414700001600428700001700444700001700461700001900478245012000497300001000617490000700627520082200634022001401456       1996                            d  c1996 Apr10aAdolescent10aAdult10aAged10aAnti-Infective Agents10aChild10aDrug Therapy, Combination10aFemale10aFollow-Up Studies10aHumans10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aOfloxacin10aPrognosis10aRifampin1 aSampoonachot P1 aBundit C1 aKuhacharoen N1 aPeerapakorn S1 aKampirapap K1 aPoomlek A1 aBampenyu S1 aTiasiri S1 aRungruang S1 aSurasondhi S1 aSupanwanit S1 aWiriyawipart S00aCombined chemotherapy trials with regimens containing ofloxacin and rifampicin for multibacillary leprosy patients.  a210-70 v793 a<p>The results of combined chemotherapy trials with regimens containing ofloxacin and rifampicin for the treatment of 60 multibacillary leprosy cases from January 1989 to September 1995 was reported. Clinical improvement was achieved by all regimens from the end of the first month. Most patients continued to improve for 3 years. Bacterial indices were gradually reduced during the treatment. Patients on regimens containing rifampicin were clear of M. leprae at the end of the 5th year. The complications and side-effects of ofloxacin and rifampicin were trivial and both drugs were well tolerated. Ofloxacin added to the current WHO recommended M.B.-MDT regimen may shorten the duration of treatment. Ofloxacin may be an alternative in suspected/proven rifampicin resistant cases or rifampicin contraindicated.</p>  a0125-2208